What's on this Page
Fibrinogen Concentrate Human Brand Names- FIBRYGA | RiaSTAP
What is Fibrinogen Concentrate Human
Fibrinogen concentrate is a purified, lyophilized fibrinogen powder manufactured from pooled human plasma.
Fibrinogen concentrate is indicated for the treatment of acute bleeding in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
Congenital fibrinogen deficiency is a rare genetic disease with an estimated incidence of 1 to 2 per million in the general population.
Without treatment, patients with this condition are at risk for life-threatening bleeding. Prior to the approval of fibrinogen concentrate, correction of fibrinogen deficiencies occurred via administration of cryoprecipitate or fresh frozen plasma (FFP) infusions.
Fibrinogen concentrate maintains several advantages over cryoprecipitate and FFP including purification during the production process, dose standardization to target fibrinogen concentrations, and minimization of the infusion volume.
Spontaneous thrombosis may occur in patients with congenital fibrinogen deficiency with or without the use of fibrinogen replacement therapy; thromboembolic events have been reported in patients receiving fibrinogen concentrate.
Indications
- afibrinogenemia
- hemorrhage
- hypofibrinogenemia
For the treatment of acute bleeding episodes (i.e., hemorrhage) in patients with congenital fibrinogen deficiency including afibrinogenemia and hypofibrinogenemia
Side Effects
- anaphylactoid reactions
- chills
- dizziness
- dyspnea
- erythema
- fever
- headache
- hypotension
- myocardial infarction
- nausea
- pruritus
- pulmonary embolism
- rash
- skin irritation
- thromboembolism
- thrombosis
- vomiting
- weakness
Monitoring Parameters
- fibrinogen
Contraindications
- albumin hypersensitivity
- breast-feeding
- children
- infection
- pregnancy
- thromboembolic disease
Interactions
There are no drug interactions associated with Fibrinogen Concentrate, Human products.
